Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aeglea BioTherapeutics stock in Canada | $7.7

Own Aeglea BioTherapeutics shares in just a few minutes.

Aeglea BioTherapeutics Inc
- $0.02 ( - 0.26%)

Aeglea BioTherapeutics is a biotechnology business based in the US. Aeglea BioTherapeutics stocks (AGLE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.13 – an increase of 8.6% over the previous week. Aeglea BioTherapeutics employs 91 staff and has a trailing 12-month revenue of around $13.7 million.

How to buy Aeglea BioTherapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AGLE in this case.
  5. Research Aeglea BioTherapeutics stocks. The platform should provide the latest information available.
  6. Buy your Aeglea BioTherapeutics stocks. It's that simple.

Is it a good time to buy Aeglea BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Aeglea BioTherapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Aeglea BioTherapeutics's stock price has had significant negative movement.

Its last market close was $7.7, which is 2.16% down on its pre-crash value of $7.87 and 120.00% up on the lowest point reached during the March crash when the stocks fell as low as $3.5.

If you had bought $1,000 worth of Aeglea BioTherapeutics stocks at the start of February 2020, those stocks would have been worth $557.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,029.41.

Aeglea BioTherapeutics stock price

Use our graph to track the performance of AGLE stocks over time.

Aeglea BioTherapeutics stocks at a glance

Information last updated 2021-09-17.
Latest market close$7.7
52-week range$5.82 - $9.9
50-day moving average $6.846
200-day moving average $7.1986
Wall St. target price$14.5
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.017

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Aeglea BioTherapeutics price performance over time

Historical closes compared with the last close of $7.7

1 week (2021-09-16) 8.60%
1 month (2021-08-23) 7.84%
3 months (2021-06-23) 17.92%
6 months (2021-03-23) -9.52%
1 year (2020-09-23) 11.92%
2 years (2019-09-23) -6.10%
3 years (2018-09-21) -15.94%
5 years (2016-09-23) 18.64%

Aeglea BioTherapeutics financials

Revenue TTM USD$13.7 million
Gross profit TTM USD$-59,638,000
Return on assets TTM -25.72%
Return on equity TTM -48.51%
Profit margin 0%
Book value $2.428
Market capitalisation USD$366.5 million

TTM: trailing 12 months

How to short and sell Aeglea BioTherapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AGLE.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.0 million Aeglea BioTherapeutics stocks held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 2.3% down from 1.0 million last month.

There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics stocks can be evaluated.

Aeglea BioTherapeutics's "short interest ratio" (SIR)

Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics stocks currently shorted divided by the average quantity of Aeglea BioTherapeutics stocks traded daily (recently around 127097.72727273). Aeglea BioTherapeutics's SIR currently stands at 7.92. In other words for every 100,000 Aeglea BioTherapeutics stocks traded daily on the market, roughly 7920 stocks are currently held short.

However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics stocks, or, against the total number of tradable Aeglea BioTherapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Aeglea BioTherapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0308% of the tradable stocks (for every 100,000 tradable Aeglea BioTherapeutics stocks, roughly 31 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Aeglea BioTherapeutics.

Find out more about how you can short Aeglea BioTherapeutics stock.

Aeglea BioTherapeutics stock dividends

We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Aeglea BioTherapeutics stock price volatility

Over the last 12 months, Aeglea BioTherapeutics's stocks have ranged in value from as little as $5.82 up to $9.9. A popular way to gauge a stock's volatility is its "beta".

AGLE.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6681. This would suggest that Aeglea BioTherapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea BioTherapeutics overview

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Stocks similar to Aeglea BioTherapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site